DNMT3A and acute myeloid leukemia: A trial on gemcitabine resistance in AML showed that among 122 patients in a combined phase I and phase II cohorts, cluster R (resistant) patients characterized by downregulated DNMT1 and upregulated DNMT3A/DNMT3B were resistant to gemcitabine, with composite complete response (CRc) observed in 0/27 (0%) patients and 28/95 (29%) patients for cluster S (sensitive) (p = 0.0005).